News Image

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Provided By GlobeNewswire

Last update: Aug 13, 2025

CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.  

Read more at globenewswire.com

BIOVIE INC

NASDAQ:BIVI (8/22/2025, 8:00:02 PM)

After market: 1.6554 +0.06 (+3.46%)

1.6

+0.08 (+5.26%)



Find more stocks in the Stock Screener

BIVI Latest News and Analysis

Follow ChartMill for more